EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study

Alessia Perrucci, Maria De Bonis, Giulia Maneri iD, Claudio Ricciardi Tenore, Paola Concolino iD, Matteo Corsi, Alessandra Conca, Jessica Evangelista, Alessia Piermattei iD, Camilla Nero iD, Luciano Giacò iD, Elisa De Paolis iD und 2 weitere

Genes · 08.09.2025 · 16 (9) · 1052

DOI: 10.3390/genes16091052 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Genes, online erschienen am 08.09.2025. Verfasst von Alessia Perrucci und 13 weiteren Autor:innen. Beteiligte Einrichtung: Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Gemelli IRCCS, 00168 Rome, Italy. Hauptthemen laut MEDLINE: Ovarian Neoplasms, BRCA1 Protein, High-Throughput Nucleotide Sequencing, BRCA2 Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Copy number variations (CNVs), also referred to as large genomic rearrangements (LGRs), represent a crucial component of BRCA1/2 (BRCA) testing. Next-generation sequencing (NGS) has become an established approach for detecting LGRs by combining sequencing data with dedicated bioinformatics pipelines. However, CNV detection in formalin-fixed paraffin-embedded (FFPE) samples remains technically challenging, and there is the need to implement a robust and optimized analysis strategy for routine clinical practice.

Methods

This study evaluated 40 FFPE ovarian cancer (OC) samples from patients undergoing BRCA testing. The performance of the amplicon-based NGS Diatech Myriapod® NGS BRCA1/2 panel (Diatech Pharmacogenetics, Jesi, Italy) was assessed for its ability to detect BRCA CNVs and results were compared to two hybrid capture-based reference assays.

Results

Among the 40 analyzed samples (17 CNV-positive and 23 CNV-negative for BRCA genes), the Diatech pipeline showed a good concordance with the reference method—all CNVs were correctly identified in 16 cases with good enough sequencing quality. Only one result was inconclusive due to low sequencing quality.

Conclusions

These findings support the clinical utility of NGS-based CNV analysis in FFPE samples when combined with appropriate bioinformatics tools. Integrating visual inspection of CNV plots with automated CNV calling improves the reliability of CNV detection and enhances the interpretation of results from tumor tissue. Accurate CNV detection directly from tumor tissue may reduce the need for additional germline testing, thus shortening turnaround times. Nevertheless, blood-based testing remains mandatory to determine whether detected BRCA CNVs are of hereditary or somatic origin, particularly in cases with a strong clinical suspicion of inherited predisposition due to young age and a personal and/or family history of OC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsBRCA1 ProteinHigh-Throughput Nucleotide SequencingBRCA2 ProteinDNA Copy Number VariationsGene RearrangementHumansFemaleParaffin EmbeddingMiddle AgedGenetic TestingAdult

Stichwörter der Autor:innen

BRCA genesDiatech Myriapod® NGS BRCA1/2 panel kitFPG500NGSSOPHiA DDM™ Homologous Recombination Solutioncopy number variationslarge genomic rearrangementsovarian cancer

Substanzen

BRCA1 ProteinBRCA2 ProteinBRCA1 protein, humanBRCA2 protein, human

Autor:innen und Institutionen

  • Departmental Unit of Molecular and Genomic Diagnostics, Fondazione Policlinico Gemelli IRCCS, 00168 Rome, Italy.
  • Genomics Core Facility, G-STeP, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Pathology Unit, Department of Woman and Child's Health and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Unit of Oncological Gynecology, Department of Women, Children and Public Health Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Department of Women, Children and Public Health Sciences Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Bioinformatics Research Core Facility, Gemelli Science and Technology Park (G-STeP), Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.

ORCID-Profile: Giulia Maneri, Paola Concolino, Alessia Piermattei, Camilla Nero, Luciano Giacò, Elisa De Paolis, Anna Fagotti, Angelo Minucci

Zitieren

APA

Perrucci, A., De Bonis, M., Maneri, G., Ricciardi Tenore, C., Concolino, P., Corsi, M., Conca, A., Evangelista, J., Piermattei, A., Nero, C., Giacò, L., De Paolis, E., Fagotti, A., & Minucci, A. (2025). Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study. Genes, 16(9), 1052. https://doi.org/10.3390/genes16091052

Vancouver

Perrucci A, De Bonis M, Maneri G, Ricciardi Tenore C, Concolino P, Corsi M, et al. Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study. Genes. 2025;16(9):1052. doi:10.3390/genes16091052

BibTeX
@article{Perrucci2025,
  author = {Perrucci, Alessia and De Bonis, Maria and Maneri, Giulia and Ricciardi Tenore, Claudio and Concolino, Paola and Corsi, Matteo and Conca, Alessandra and Evangelista, Jessica and Piermattei, Alessia and Nero, Camilla and Giacò, Luciano and De Paolis, Elisa and Fagotti, Anna and Minucci, Angelo},
  title = {Detection of Clinically Significant BRCA Large Genomic Rearrangements in FFPE Ovarian Cancer Samples: A Comparative NGS Study},
  journal = {Genes},
  year = {2025},
  volume = {16},
  number = {9},
  pages = {1052},
  doi = {10.3390/genes16091052}
}
Kostenlos starten →